Advertisement
Original research| Volume 1, ISSUE 2, P106-111, April 2008

Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4-week randomized placebo controlled study

      Background

      In the absence of effective treatments for the negative symptom complex of schizophrenia, we explored the effect of 4 consecutive weeks of repetitive transcranial magnetic stimulation (rTMS) exposure (20 sessions) as an add-on treatment to atypical antipsychotics.

      Methods

      Three groups of 17 schizophrenic subjects each were exposed to 20 treatments of either placebo, 1 Hz (100 pulses per day=2000 total) or 10 Hz (1000 pulses per day=20,000 total) rTMS at 110% motor threshold over the left dorsolateral prefrontal cortex, while being maintained on their atypical antipsychotic. Subjects were evaluated at baseline, weeks 2 and 4, and at 4-week follow-up after the last treatment.

      Results

      The primary outcome measure (change in Scale for Assessment of Negative Symptoms score) showed a statistically significant drop at weeks 2, 4, and 8 for the high frequency (10 Hz) group, but not the 1 Hz or placebo groups. Secondary outcome measures of the Wisconsin Card Sorting Test and SF-36 did not demonstrate any significant change.

      Conclusions

      rTMS may serve as a relatively noninvasive treatment of the negative and neurocognitive deficits associated with schizophrenia.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Andreasen N.C.
        • Flaum M.
        • Swayze V.W.
        • et al.
        Positive and negative symptoms in schizophrenia: a critical reappraisal.
        Arch Gen Psychiatr. 1990; 47: 615-621
        • Tamminga C.A.
        • Buchanan R.W.
        • Gold J.M.
        The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.
        Int Clin Psychopharmacol. 1998; 13: S21-S26
        • Dollfus S.
        • Petit M.
        Negative symptoms in schizophrenia: their evolution during an acute phase.
        Schizophr Res. 1995; 17: 187-194
        • Nelson E.B.
        • Sax K.W.
        • Strakowski S.M.
        Attentional performance in patients with psychotic and nonpsychotic major depression and schizophrenia.
        Am J Psychiat. 1998; 155: 137-139
        • Wing J.K.
        The concept of negative symptoms.
        Br J Psych Suppl. 1989; 7: 10-14
        • Penades R.
        • Gasto C.
        • Boget T.
        • et al.
        Deficit in schizophrenia: the relationship between negative symptoms and neurocognition.
        Compr Psychiatry. 2001; 42: 64-69
        • Kolb B.
        • Whishaw I.Q.
        Performance of schizophrenic patients on tests sensitive to left or right frontal temporal parietal function in neurological patients.
        J Nerv Ment Dis. 1983; 171: 435-443
        • Taylor M.A.
        • Abrams R.
        Cognitive impairment in schizophrenia.
        Am J Psychiat. 1984; 141: 196-201
        • Weinberger D.R.
        • Berman K.F.
        • Zec R.F.
        Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia.
        Arch Gen Psychiat. 1986; 43: 114-124
        • Lecours A.R.
        • Mehler J.
        • Parente M.A.
        • et al.
        Illiteracy and brain damage: a contribution to the study of speech and language disorders in illiterates with unilateral brain damage (initial testing).
        Neuropsychologia. 1988; 26: 575-589
        • Poulet E.
        • Brunelin J.
        • Bediou B.
        • et al.
        Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia.
        Biol Psychiatry. 2005; 57: 188-191
        • George M.S.
        • Nahas Z.
        • Borckardt J.J.
        • et al.
        Brain stimulation for the treatment of psychiatric disorders.
        Curr Opin Psychiatry. 2007; 20 (discussion 247–249): 250-254
        • Aleman A.
        • Sommer I.E.
        • Kahn R.S.
        Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis.
        J Clin Psychiatry. 2007; 68: 416-421
        • Saba G.
        • Verdon C.M.
        • Kalalou K.
        • et al.
        Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study.
        J Psychiatr Res. 2006; 40: 147-152
        • Novak T.
        • Horacek J.
        • Mohr P.
        • et al.
        The double-blind sham-controlled study of high-frequency rTMS (20Hz) for negative symptoms in schizophrenia: negative results.
        Neuro Endocrinol Lett. 2006; 27: 209-213
        • Cordes J.
        • Arends M.
        • Mobascher A.
        • et al.
        Potential clinical targets of repetitive transcranial magnetic stimulation treatment in schizophrenia.
        Neuropsycholobiology. 2006; 54: 87-99
        • Jandl M.
        • Steyer J.
        • Weber M.
        • et al.
        Treating auditory hallucinations by transcranial magnetic stimulation: a randomized controlled cross-over trial.
        Neuropsychobiology. 2006; 53: 63-69
        • McIntosh A.M.
        • Semple D.
        • Tasker K.
        • et al.
        Transcranial magnetic stimulation for auditory hallucinations in schizophrenia.
        Psychiatry Res. 2004; 127: 9-17
        • Prikryl R.
        • Kasparek T.
        • Skotakova S.
        • et al.
        Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study.
        Schizophr Res. 2007; 95: 151-157
        • Mogg A.
        • Purvis R.
        • Eranti S.
        • et al.
        Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study.
        Schizophr Res. 2007; 93: 221-228
        • Fitzgerald P.B.
        • Benitez J.
        • Daskalakis J.Z.
        • et al.
        The treatment of recurring auditory hallucinations in schizophrenia with rTMS.
        World J Biol Psychiatry. 2006; 7: 119-122
        • Ragert P.
        • Dinse H.R.
        • Pleger B.
        • et al.
        Combination of 5 Hz repetitive transcranial magnetic stimulation (rTMS) and tactile coactivation boosts tactile discrimination in humans.
        Neurosci Lett. 2003; 348: 105-108
        • Knecht S.
        • Ellger T.
        • Breitenstein C.
        • et al.
        Changing cortical excitability with low-frequency transcranial magnetic stimulation can induce sustained disruption of tactile perception.
        Biol Psychiatry. 2003; 53: 175-179
        • Ben-Shachar D.
        • Gazawi H.
        • Riboyad-Levin J.
        • et al.
        Chronic repetitive transcranial magnetic stimulation alters β-adrenergic and 5-HT2 receptor characteristics in rat brain.
        Brain Res. 1999; 816: 78-83
        • Kole M.H.
        • Fuchs E.
        • Ziemann U.
        • et al.
        Changes in 5-HT1A and NMDA binding sites by a single rapid transcranial magnetic stimulation procedure in rats.
        Brain Res. 1999; 826: 309-312
        • D'Souza D.C.
        • Charney D.S.
        • Krystal J.H.
        Glycine site agonists of the NMDA receptor: a review.
        CNS Drug Rev. 1995; 1: 227-260
        • Andreasen N.C.
        The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations.
        Br J Psychiatry Suppl. 1989; 7: 49-58
        • Lukoff D.
        • Nuechterlein K.H.
        • Ventura J.
        Appendix A: manual for expanded brief psychiatric rating scale (BPRS).
        Schizophr Bull. 1986; 12: 594-602
        • Heaton R.K.
        • Chelune G.J.
        • Talley J.L.
        • et al.
        Wisconsin Card Sorting Test Manual: revised and expanded.
        Florida, Odessa1993
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiat. 1960; 23: 56-62
        • Brazier J.E.
        • Harper R.
        • Jones N.M.
        • et al.
        Validating the SF-36 health survey questionnaire: new outcome measure for primary care.
        BMJ. 1992; 305: 160-164
      1. NIMH: CGI (Clinical Global Impression) scale.
        Psychopharmacol Bull. 1985; 21: 839-843
        • Janno S.
        • Holi M.M.
        • Tuisku K.
        • Wahlbeck K.
        Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population.
        BMC Neurol. 2005; 5: 5
      2. Schneider AL, Schneider T, Mason K. Acoustic threshold shift & rTMS: absence of deficits detected after 4 weeks of exposure in 51 schizophrenic subjects. Soc Biol Psychiatry 2007 May-annual meeting; poster presentation: San Diego, CA.

        • Loo C.
        • Sachdev P.
        • Elsayed H.
        • et al.
        Effects of a 2 to 4 week course of repetitive transcranial magnetic stimulation (rTMS) on neuropsychologic functioning, electroencephalogram, and auditory threshold in depressed patients.
        Biol Psychiatry. 2001; 49: 615-623
        • Anthony W.A.
        • Jansen M.A.
        Predicting the vocational capacity of the chronically mentally ill. Research and Policy Implications.
        Am Psychol. 1984; 39: 537-544
        • Bowen L.
        • Wallace C.J.
        • Glynn S.M.
        • et al.
        Schizophrenic individuals' cognitive functioning and performance in interpersonal interactions and skills training procedures.
        J Psychiatr Res. 1994; 28: 289-301
        • Fenton W.S.
        • McGlashan T.H.
        Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia.
        Am J Psychiatry. 1994; 151: 351-356
        • Patterson T.L.
        • Moscona S.
        • McKibbin C.L.
        • et al.
        Social skills performance assessment among older patients with schizophrenia.
        Schizophr Res. 2001; 48: 351-360